Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 72Breast 5Tumor-Agnostic 2Thoracic 2Plasma cell 2Sarcoma 1Other neoplasm 1Head & Neck 1

Conditions

Neoplasms 1Neoplasm Metastasis 1

Interventions

pembrolizumab 95Paclitaxel 86Gemcitabine 84Carboplatin 79Surveys and Questionnaires 72Docetaxel 61Bevacizumab 61Nivolumab 59Cisplatin 59Magnetic Resonance Spectroscopy 50Blood Specimen Collection 50Fluorouracil 48Radiotherapy 47Capecitabine 47Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 38Biopsy 36atezolizumab 35Leucovorin 35Pemetrexed 34Standard of Care 32Cetuximab 32Specimen Handling 31Trastuzumab 30Radiosurgery 29Ipilimumab 28Cyclophosphamide 28Interviews as Topic 27olaparib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
radium Ra 223 dichloride × Tumor-Agnostic × Clear all
NCT02331303 2018-01-23

A Drug Utilization Study of Radium-223 in Sweden

Bayer

Completed
37 enrolled
Tumor-Agnostic

Neoplasms

NCT01798108 2017-05-19

Dose Escalation Study of Radium-223 Dichloride in Patients With Advanced Skeletal Metastases

Bayer

Phase 1 Completed
31 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡